...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious diseases in obstetrics and gynecology >Ampicillin/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease
【24h】

Ampicillin/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease

机译：氨苄西林/舒巴坦Vs.头孢西丁治疗盆腔炎

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective:The safety and efficacy of ampicillin plus sulbactam were compared with those of cefoxitin in the treatment of women with pelvic inflammatory disease (PID).Methods:This single-site, randomized, prospective, third-party-blinded, comparative, parallel-treatment study enrolled 93 women with a diagnosis of PID. Patients were treated with either ampicillin/sulbactam (2 g/1 g, administered intravenously [IV], every 6 h) or cefoxitin (2 g, administered IV, every 6 h) for a minimum of 12 doses. Patients with cultures positive forChlamydia trachomatisalso received concurrent oral or IV doxycycline (100 mg twice daily). Patients with cultures negative forC. trachomatisreceived prophylactic oral doxycycline (100 mg twice daily) for 10–14 days after treatment with either ampicillin/sulbactam or cefoxitin was completed.Results:Ninety-three patients were entered in the study: 47 in the ampicillin/sulbactam arm and 46 in the cefoxitin arm. All 93 patients were evaluable for safety; 61 (66%) were evaluable for efficacy. Demographic characteristics were similar for the groups. Of the 27 evaluable ampicillin/sulbactam-treated patients, 67% experienced clinical cure, 30% improved, and 4% failed treatment. Respective values for the 34 cefoxitin-treated patients were 68%, 24%, and 9% (P= 0.67). Pathogens were eradicated in 70% of the women given ampicillin/sulbactam vs. 56% of those who received cefoxitin (P= 0.64).Conclusions:Overall, ampicillin/sulbactam demonstrated clinical and bacteriologic efficacy at least equivalent to that of cefoxitin in the treatment of women with acute PID. The use of ampicillin/sulbactam for this indication may avoid the complex dosing regimens associated with other treatments.
机译：目的：比较氨苄西林联合舒巴坦与头孢西丁治疗盆腔炎的女性的安全性和有效性。治疗研究招募了93名诊断为PID的女性。患者接受氨苄西林/舒巴坦（2 g / 1 g，每6 h静脉内注射[IV]）或头孢西丁（2 g，每6 h静脉内注射）治疗至少12剂。沙眼衣原体培养阳性的患者也同时接受口服或静脉注射强力霉素（每天两次100 mg）。文化C阴性的患者。在用氨苄西林/舒巴坦或头孢西丁治疗后，沙眼接受预防性口服强力霉素（每天两次，每次100 mg）治疗10-14天。结果：该研究纳入了93名患者：氨苄青霉素/舒巴坦组47例，阿昔洛韦46例。头孢西丁臂。所有93例患者的安全性均得到评估; 61例（66％）可评估疗效。各组的人口统计学特征相似。在27例接受氨苄西林/舒巴坦治疗的可评估患者中，有67％经历过临床治愈，有30％改善了治疗，4％的治疗失败。 34例接受头孢西丁治疗的患者的相应值分别为68％，24％和9％（P = 0.67）。接受氨苄西林/舒巴坦治疗的女性中70％的病原体被根除，而接受头孢西丁治疗的女性中这一比例为56％（P = 0.64）。有急性PID的女性。将氨苄西林/舒巴坦用于该适应症可以避免与其他治疗相关的复杂给药方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号